Cargando…

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial

BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Ambarish, Berry, Jarett D., Drazner, Mark H., Fang, James C, Tang, W. H. Wilson, Grodin, Justin L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404179/ https://www.ncbi.nlm.nih.gov/pubmed/30376747 http://dx.doi.org/10.1161/JAHA.118.009664

Ejemplares similares

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)

Identifying a low‐flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial
por: Patel, Kershaw V., et al.
Publicado: (2019)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial
por: Wu, Yuzhong, et al.
Publicado: (2020)

Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021)

Weight cycling and risk of clinical adverse events in patients with heart failure with preserved ejection fraction: a post-hoc analysis of TOPCAT
por: Tan, Yi, et al.
Publicado: (2023)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020)

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review
por: Pandey, Ambarish, et al.
Publicado: (2015)

Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
por: Wei, Fang‐Fei, et al.
Publicado: (2020)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

C(2)HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
por: Liang, Weihao, et al.
Publicado: (2021)

Impact of Sex on Ventricular‐Vascular Stiffness and Long‐Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy
por: Beale, Anna L., et al.
Publicado: (2019)

Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT
por: Sun, Jiaxing, et al.
Publicado: (2021)

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
por: Kim, Morris M., et al.
Publicado: (2023)

Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy
por: Matsumoto, Shingo, et al.
Publicado: (2020)

Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES
por: Hendren, Nicholas S., et al.
Publicado: (2020)

Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction
por: Tate, Samuel, et al.
Publicado: (2014)

Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Dal Canto, Elisa, et al.
Publicado: (2023)

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial
por: Neefs, Jolien, et al.
Publicado: (2019)

Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial
por: Liang, Weihao, et al.
Publicado: (2021)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
por: Dong, Bin, et al.
Publicado: (2022)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
por: Sarma, Satyam, et al.
Publicado: (2020)

Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction—a systematic review and meta-analysis
por: Remmelzwaal, Sharon, et al.
Publicado: (2020)

Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications
por: Tanase, Daniela Maria, et al.
Publicado: (2019)

Usefulness of B‐Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction
por: Liu, Xiao, et al.
Publicado: (2022)

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial
por: Saksena, Sanjeev, et al.
Publicado: (2023)

Role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Eroume-A Egom, Emmanuel, et al.
Publicado: (2020)

Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction
por: Cui, Kun, et al.
Publicado: (2018)

Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems
por: Parcha, Vibhu, et al.
Publicado: (2021)

Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial
por: Silverman, Daniel N., et al.
Publicado: (2019)

Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial
por: Sandesara, Pratik B., et al.
Publicado: (2018)

Authors’ reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2020)

Discordance Between Severity of Heart Failure as Determined by Patient Report Versus Cardiopulmonary Exercise Testing
por: Michelis, Katherine C., et al.
Publicado: (2021)

Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
por: Michelis, Katherine C., et al.
Publicado: (2020)

Associations of High‐Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT
por: Ascher, Simon B., et al.
Publicado: (2022)

Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides
por: Silva Enciso, J.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lja9cva0h12lde40g1srjrrf1i